+

WO2003015779A3 - Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol - Google Patents

Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol Download PDF

Info

Publication number
WO2003015779A3
WO2003015779A3 PCT/EP2002/008394 EP0208394W WO03015779A3 WO 2003015779 A3 WO2003015779 A3 WO 2003015779A3 EP 0208394 W EP0208394 W EP 0208394W WO 03015779 A3 WO03015779 A3 WO 03015779A3
Authority
WO
WIPO (PCT)
Prior art keywords
ropinirole
pramipexole
therapeutic system
transdermal therapeutic
controlled transdermal
Prior art date
Application number
PCT/EP2002/008394
Other languages
English (en)
French (fr)
Other versions
WO2003015779A2 (de
Inventor
Cornelia Beier
Martina Wilhelm
Original Assignee
Hexal Ag
Cornelia Beier
Martina Wilhelm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag, Cornelia Beier, Martina Wilhelm filed Critical Hexal Ag
Priority to EP02762404A priority Critical patent/EP1411937A2/de
Priority to CA002455822A priority patent/CA2455822A1/en
Priority to US10/484,876 priority patent/US7344733B2/en
Publication of WO2003015779A2 publication Critical patent/WO2003015779A2/de
Publication of WO2003015779A3 publication Critical patent/WO2003015779A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die Erfindung betrifft ein wirkstoffhaltiges, matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramipexol, Ropinirol, deren pharmazeutisch unbedenklichen Salze oder Derivate.
PCT/EP2002/008394 2001-07-28 2002-07-26 Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol WO2003015779A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02762404A EP1411937A2 (de) 2001-07-28 2002-07-26 Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol
CA002455822A CA2455822A1 (en) 2001-07-28 2002-07-26 Matrix controlled transdermal therapeutic system for the use of pramipexole and ropinirole
US10/484,876 US7344733B2 (en) 2001-07-28 2002-07-26 Matrix controlled transdermal therapeutic system for the use of pramipexole and ropinirole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10137082A DE10137082A1 (de) 2001-07-28 2001-07-28 Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
DE10137082.2 2001-07-28

Publications (2)

Publication Number Publication Date
WO2003015779A2 WO2003015779A2 (de) 2003-02-27
WO2003015779A3 true WO2003015779A3 (de) 2003-10-23

Family

ID=7693589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008394 WO2003015779A2 (de) 2001-07-28 2002-07-26 Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol

Country Status (5)

Country Link
US (1) US7344733B2 (de)
EP (1) EP1411937A2 (de)
CA (1) CA2455822A1 (de)
DE (1) DE10137082A1 (de)
WO (1) WO2003015779A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10060852A1 (de) * 2000-12-06 2002-06-20 Hexal Ag Absorptionsmittel und Kanalbildner enthaltende wirkstoffundurchlässige Deckschicht oder abziehbare Schutzschicht eines transdermalen therapeutischen Systems
DE10137162A1 (de) * 2001-07-30 2003-02-20 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
EP2305252A1 (de) * 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Verwendung von Pramipexol zur Behandlung amyotropher Lateralsklerose
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
US20080234338A1 (en) * 2005-08-15 2008-09-25 University Of Virginia Patent Foundation Neurorestoration With R(+) Pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007137071A2 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods of using the same
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
RU2454409C2 (ru) 2007-03-14 2012-06-27 Нопп Ньюросайенсиз, Инк. Синтез хирально очищенных замещенных бензотиазолдиаминов
CA2734491A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
EP2459225A1 (de) * 2009-07-31 2012-06-06 Ascendis Pharma A/S An einen träger gebundene pramipexol-prodrugs
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
US10149834B2 (en) * 2011-12-01 2018-12-11 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
CA2857156C (en) * 2011-12-01 2019-09-24 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
DE102012205493A1 (de) * 2012-04-03 2013-10-10 Acino Ag Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
EP2999444A4 (de) * 2013-05-20 2016-10-12 Mylan Inc Erweiterte transdermale dosierung von pramipexol zur behandlung von neurologischen erkrankungen
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
CN109310526B (zh) * 2016-10-07 2022-05-17 全崴生技股份有限公司 普拉克索经皮贴片系统与用法
WO2018155390A1 (ja) * 2017-02-24 2018-08-30 久光製薬株式会社 貼付剤及びその包装体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462744A (en) * 1989-12-01 1995-10-31 Boehringer Ingelheim Kg Transdermal system for the administration of pharmacological compounds under pH-controlled conditions
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
DE19814084A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
EP1027889A2 (de) * 1991-05-18 2000-08-16 Schering Aktiengesellschaft Mittel zur transdermalen Applikation enthaltend Ergolin-Derivate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE4313402A1 (de) * 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermale Wirkstoffzubereitung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462744A (en) * 1989-12-01 1995-10-31 Boehringer Ingelheim Kg Transdermal system for the administration of pharmacological compounds under pH-controlled conditions
EP1027889A2 (de) * 1991-05-18 2000-08-16 Schering Aktiengesellschaft Mittel zur transdermalen Applikation enthaltend Ergolin-Derivate
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
DE19814084A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
US7344733B2 (en) 2008-03-18
DE10137082A1 (de) 2003-02-13
EP1411937A2 (de) 2004-04-28
WO2003015779A2 (de) 2003-02-27
CA2455822A1 (en) 2003-02-27
US20040247656A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2003015779A3 (de) Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
WO2002002525A3 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
AU2002321199A1 (en) Transdermal therapeutic system (TTS) with fentanyl as active ingredient
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2002007721A3 (en) Use of cox-2 inhibitors for preventing immunodeficiency
EP1440691A3 (de) Behandlung von neurotischen Erkrankungen
WO2001098270A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2001098269A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2002332488A1 (en) R-bambuterol, its preparation and therapeutic uses
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
CA2370834A1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
JP2002542281A5 (de)
AU2001228810A1 (en) Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
WO1999056734A3 (de) Transdermales therapeutisches system zur anwendung von candesartan
BG106151A (en) Pharmaceutical complex
WO2001068063A3 (en) Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
AU1556000A (en) Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
WO2001007038A3 (en) Use of l-carnitine and its alkanoyl derivatives for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy
AU1556601A (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
AU2001274000A1 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
AU2502301A (en) Medicament and combination of compatible medicaments
AU2002225097A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002762404

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2455822

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002762404

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10484876

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载